Daewoong introduces Tillots's Asacol in Korea

Published: 2004-11-22 06:57:00

Updated: 2004-11-22 06:57:00

Daewoong Pharm said it has launched Asacol (mesalazine) in the domestic market, which is the leading drug worldwide for the treatment of Inflammatory Bowel Disease (IBD). It signed a licensing agreement for the exclusive marketing rights for Korea.

The product was developed and first launched ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK